Canagliflozin

Sana Biotechnology Announces the Appointment of Two Pioneers in Drug Discovery and Development to Lead its R&D Organization

Retrieved on: 
Monday, April 10, 2023
Amgen, ZymoGenetics, Biotechnology, Drug development, Executive, Senior, University, Seagen, Biogen, Binghamton University, University School, State university system, Drug, Janssen, Massachusetts General Hospital, Buffalo, Bristol Myers Squibb, Canagliflozin, Biology, Buffalo buffalo Buffalo buffalo buffalo buffalo Buffalo buffalo, Merck & Co., Organization, Research and development, Development, Patient, New York University Grossman School of Medicine, Robert Wood Johnson University Hospital, Internal medicine, University of Massachusetts Lowell, IND World's Fair Line, Genetic, Hospital, SANA, IND, Research and Development Council of New Jersey, Management, Pharmaceutical industry, Vertex, Endocrinology, Merck, Research

SEATTLE, April 10, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointments of two senior leaders to its research and development organization, Douglas E. Williams, Ph.D., as President of Research and Development, and Gary Meininger, M.D., as Chief Medical Officer. In a planned transition, Sunil Agarwal, M.D., Chief Medical Officer, will leave the company after helping onboard these new executives.

Key Points: 
  • In a planned transition, Sunil Agarwal, M.D., Chief Medical Officer, will leave the company after helping onboard these new executives.
  • In his career, he has participated in the development of over a dozen approved medicines across multiple therapeutic areas, including multiple blockbusters.
  • Dr. Meininger has over two decades of experience in drug development leadership, most recently at Vertex and previously at both Janssen and Merck.
  • He is currently the industry representative to the FDA’s Endocrine and Metabolic Drug Advisory Committee.

Havas Health & You Appoints Industry Veteran David Leonardi as Chief Creative Officer of Havas Tonic

Retrieved on: 
Wednesday, June 8, 2022
Lynx, Leadership, Secukinumab, Health, DTC, OTC, BBDO, Partnership, Multimedia, HH, CVS Health, Technology, Culture, Ogilvy, Tonic, View, Today, CCO, News, Nightclub, Canagliflozin

NEW YORK, June 8, 2022 /PRNewswire/ -- As the needs of modern health and wellness brands continue to evolve, Havas Health & You (HH&Y) today announced the network will bring on industry-leading creative veteran David Leonardi as Chief Creative Officer (CCO) of Havas Tonic, its largest consumer-focused health and wellness agency. David will join Havas Tonic on June 6th, working closely with Tonic's Managing Director Corey Cirillo and HH&Y Global CCO Eric Weisberg to rethink the future of Havas Tonic as a direct response to the expanding needs of the consumer health and wellness brands of today and tomorrow.

Key Points: 
  • NEW YORK, June 8, 2022 /PRNewswire/ -- As the needs of modern health and wellness brands continue to evolve, Havas Health & You (HH&Y) today announced the network will bring on industry-leading creative veteran David Leonardi as Chief Creative Officer (CCO) of Havas Tonic, its largest consumer-focused health and wellness agency.
  • Earlier in his career, David held important creative leadership roles at Ogilvy NY and Merkley+Partners.
  • David will report to Eric Weisberg in his new role, while partnering with Corey to craft Havas Tonic's dynamic future.
  • Havas Health & You unites Havas Life, Health4Brands (H4B), Lynx, Red Havas and Havas Health Plus, all wholly owned health and communications networks, with the consumer health businesses and practices of Havas Creative Group.

Havas Health & You Appoints Industry Veteran David Leonardi as Chief Creative Officer of Havas Tonic

Retrieved on: 
Wednesday, June 8, 2022
Lynx, Leadership, Secukinumab, Health, DTC, OTC, BBDO, Partnership, HH, CVS Health, Technology, Culture, Ogilvy, Tonic, Today, CCO, News, Nightclub, Canagliflozin

NEW YORK, June 8, 2022 /PRNewswire/ -- As the needs of modern health and wellness brands continue to evolve, Havas Health & You (HH&Y) today announced the network will bring on industry-leading creative veteran David Leonardi as Chief Creative Officer (CCO) of Havas Tonic, its largest consumer-focused health and wellness agency. David will join Havas Tonic on June 6th, working closely with Tonic's Managing Director Corey Cirillo and HH&Y Global CCO Eric Weisberg to rethink the future of Havas Tonic as a direct response to the expanding needs of the consumer health and wellness brands of today and tomorrow.

Key Points: 
  • NEW YORK, June 8, 2022 /PRNewswire/ -- As the needs of modern health and wellness brands continue to evolve, Havas Health & You (HH&Y) today announced the network will bring on industry-leading creative veteran David Leonardi as Chief Creative Officer (CCO) of Havas Tonic, its largest consumer-focused health and wellness agency.
  • David will report to Eric Weisberg in his new role, while partnering with Corey to craft Havas Tonic's dynamic future.
  • Corey states, "I am ecstatic to unlock the next era of Havas Tonic in partnership with David.
  • Havas Health & You unites Havas Life, Health4Brands (H4B), Lynx, Red Havas and Havas Health Plus, all wholly owned health and communications networks, with the consumer health businesses and practices of Havas Creative Group.

KidneyIntelX™ Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient Cohort

Retrieved on: 
Monday, June 6, 2022
Hospital, Death, Adult, EGFR, DO, Centers for Disease Control and Prevention, Kidney disease, Degenerative disease, De novo, Type 2 diabetes, Food, American Diabetes Association, LSE, Risk assessment, Annual report, Standard of care, Security (finance), Form 20-F, Disease, U.S. Securities and Exchange Commission, Heart failure, Chronic kidney disease, Physician, Intelligence, SALT, Center, Cardiovascular disease, FDA, Risk, GLOBE, Patient, DKD, MS, Diabetes, Review, Private Securities Litigation Reform Act, T2D, COVID-19, NASDAQ, SEC, NEW, Population, Public health, Efficiency, CKD, Regulation of tobacco by the U.S. Food and Drug Administration, Pharmaceutical industry, Canagliflozin

NEW YORK and SALT LAKE CITY, June 06, 2022 (GLOBE NEWSWIRE) -- Renalytix (NASDAQ: RNLX) (LSE: RENX) today announced that KidneyIntelX™ successfully risk-stratified adult patients with type 2 diabetes and early-stage chronic kidney disease (stages 1 through 3) for key clinical outcomes, including heart failure hospitalizations and death. Individuals with diabetic kidney disease (DKD) are not only at risk of kidney disease progression, but also face an increased risk of heart failure and death, due to the significant interconnection of the cardiovascular, renal, and metabolic systems.

Key Points: 
  • Individuals with diabetic kidney disease (DKD) are not only at risk of kidney disease progression, but also face an increased risk of heart failure and death, due to the significant interconnection of the cardiovascular, renal, and metabolic systems.
  • Application of KidneyIntelX to this population showed that those with high-risk KidneyIntelX scores were at a three-fold higher risk for hospitalization for heart failure, severe kidney disease progression or death.
  • This data reinforces the benefit of KidneyIntelX in better informing primary care physicians who treat patients with early diabetic kidney disease (stages 1 through 3).
  • Diabetic kidney disease related metabolic conditions, including heart disease, chronic kidney disease and diabetes, are the leading causes of death worldwide and account for up to 20 million deaths in the U.S. annually.

Spherix Uncovers Key Differences in the Management of Chronic Kidney Disease Patients in Europe Versus the U.S.

Retrieved on: 
Monday, April 25, 2022
EMA, SGLT2, DKD, Astellas Pharma, Neurology, Canagliflozin, Chronic kidney disease, Population, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Nephrology, Dermatology, EMPA, NASA RealWorld-InWorld Engineering Design Challenge, Vifor Pharma, Food, European Medicines Agency, Hyperkalemia, Anemia, HIF, Patient, Gastroenterology, Dialysis, Growth, Potassium, Geography, CKD, AstraZeneca, HIV disease progression rates, FDA, Record, Kidney disease, Pharmaceutical industry, Medical device, Sodium zirconium cyclosilicate, EU, Empagliflozin, Patiromer

EXTON, Pa., April 25, 2022 /PRNewswire/ -- The approval of several renal pipeline products in the European market has granted nephrologists new options through which they can manage their patients with chronic kidney disease (CKD) – a population plagued with comorbidities and risks associated with disease progression. With the European Medicines Agency (EMA) trumping the U.S. Food and Drug Administration (FDA) in its approval and use of novel agents (e.g., EVREZNO [roxadustat]), Spherix experts have found notable differences in nephrologists' treatment patterns between the two geographies.

Key Points: 
  • One of the most notable dissimilarities was in the use of SGLT2 inhibitors.
  • Indeed, nearly one-half of EU non-dialysis patients with DKD were currently being treated with an SGLT2 inhibitor compared to the one-third of DKD patients across the pond in the US.
  • Overall uptake of SGLT2 inhibitors in non-diabetic patients has been slow but is poised for growth in the near future.
  • Alternatively, in the EU, the EMA approved Astella's HIF-PH inhibitor, EVRENZO, and uptake has been happening very gradually across the region.

IgA Nephropathy Market Shakes Up with Tarpeyo (Calliditas) Launch and Surge in Physician Prescribing of SGLT2 Inhibitors, Spherix Reports

Retrieved on: 
Monday, March 28, 2022
Optimism, NASA RealWorld-InWorld Engineering Design Challenge, Population, SGLT2, Janssen, Dialysis, ESRD, Biopsy, Lists of people executed in the United States, Canagliflozin, Research, Prescription, AstraZeneca, Nephrology, Dapagliflozin, DAPA, CKD, Physician, EGFR, Awareness, Patient, Medical device, Pharmaceutical industry, IgA nephropathy

EXTON, Pa. , March 28, 2022 /PRNewswire/ -- IgA nephropathy (IgAN) is generally recognized as the most common glomerular nephritis disease globally, impacting many patients and often resulting in ESRD and dialysis or transplant. With a bursting pipeline and the first product, Calliditas' Tarpeyo, recently gaining approval specifically for the treatment of IgAN, there is cause for optimism for patients and prescribers alike.

Key Points: 
  • With a bursting pipeline and the first product, Calliditas' Tarpeyo, recently gaining approval specifically for the treatment of IgAN, there is cause for optimism for patients and prescribers alike.
  • Spherix has been closely tracking the IgAN market for several years, covering physician perspectives, treatment patterns, and pipeline expectations since 2017.
  • This coverage has included in-depth interviews with key opinion leaders (KOLs) and "in-the-trenches" physicians, along with large-scale attitudinal surveys and chart audits of more than 900 patients.
  • In its latest research, Spherix just released the 2022 audit included in RealWorld Dynamix: IgA Nephropathy (US), analyzing 439 IgAN patient records in collaboration with 156 US based nephrologists.

SGLT2 Inhibitors Are Gaining Momentum in Chronic and Diabetic Kidney Disease, New Spherix Data Reveals

Retrieved on: 
Tuesday, March 8, 2022
Mark (given name), American Association of Clinical Endocrinologists, Kidney disease, HCP, Type 2 diabetes, Research, Particle-size distribution, Dermatology, Nephrology, AstraZeneca, Diabetes, Prescription, CKD, Gastroenterology, NASA RealWorld-InWorld Engineering Design Challenge, DKD, PCP, Patient, Wane, Appetite, Neurology, SGLT2, Population, Cardiology, Spironolactone, Novo Nordisk, Growth, Disease, Pharmaceutical industry, Bayer, Semaglutide, Canagliflozin

The approvals of Invokana (Vifor/Janssen) for diabetic kidney disease (DKD) and Farxiga (AstraZeneca) for use in both general chronic kidney disease (CKD) and DKD have opened the doors for SGLT2 inhibitors to be potentially powerful treatment options.

Key Points: 
  • The approvals of Invokana (Vifor/Janssen) for diabetic kidney disease (DKD) and Farxiga (AstraZeneca) for use in both general chronic kidney disease (CKD) and DKD have opened the doors for SGLT2 inhibitors to be potentially powerful treatment options.
  • Prescribing for these agents is increasing rapidly in DKD patients, who make up close to one-half of CKD non-dialysis patients.
  • In CKD patients without Type 2 diabetes, nephrologists' prescribing of SGLT2 inhibitors has understandably been slower than in their DKD patients.
  • Overall, nephrologists are more aligned now than they were a year ago on increasing their use of SGLT2 inhibitors in all CKD patients.

KidneyIntelX™ Clinical Results Presented at World Congress of Nephrology Demonstrate Improved Prediction of Kidney Function Over Standard of Care

Retrieved on: 
Thursday, February 24, 2022
GLOBE, Risk, Entrepreneurship, Genetics, Therapy, CDC, Physician, Glucose, Canagliflozin, Kidney disease, Population, SALT, Mount Sinai, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Prognosis, CKD, NASDAQ, SBP, Public health, Center, Centers for Disease Control and Prevention, Chronic kidney disease, Pharmacy, Glomerular filtration rate, Kidney, Coca, Nephrology, MS, Food, Biomarker, Blood pressure, Breast, Dialysis, DO, Type 2 diabetes, Albuminuria, Patient, 2021 Essex County Council election, LSE, Quality of life, Congress, EHR, DKD, Confusion, Kidney failure, Glycated hemoglobin, Icahn School of Medicine at Mount Sinai, EGFR, Pharmaceutical industry, Medical imaging, Medicine

The data results presented also showed the ability to use KidneyIntelX in conjunction with clinical features to reinforce the beneficial effects of new therapeutics in the same population.

Key Points: 
  • The data results presented also showed the ability to use KidneyIntelX in conjunction with clinical features to reinforce the beneficial effects of new therapeutics in the same population.
  • Most importantly, KidneyIntelX can help improve the quality of life for patients by enabling primary care physicians to mitigate risk at the earliest stages of kidney disease.
  • KidneyIntelX is the only early-stage, bioprognostic solution for kidney health, and has received Breakthrough Device Designation from the U.S. Food and Drug Administration.
  • This patient risk score enables prediction of progressive kidney function decline in CKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.

Positive Study Results Published for KidneyIntelX™ in Monitoring Patient Response to New Drug Therapy

Retrieved on: 
Tuesday, January 11, 2022
Population health, CDC, Association, Biomarker, Patient, Risk assessment, DKD, Center, CKD, Precision medicine, Regulation of tobacco by the U.S. Food and Drug Administration, Centers for Disease Control and Prevention, NASDAQ, Plasma, GLOBE, American Journal, Public health, EGFR, Time, Canagliflozin, Kidney disease, Chronic kidney disease, Prognosis, Diabetes, LSE, SALT, Risk, Food, Breast, Dialysis, Conditional sentence, Physician, Machine learning, Pharmaceutical industry, Medical device, Nephrology

Monitoring response to new medications over time is a core part of precision medicine utility for chronic kidney disease control, which could be enabled by KidneyIntelX to provide improved patient care.

Key Points: 
  • Monitoring response to new medications over time is a core part of precision medicine utility for chronic kidney disease control, which could be enabled by KidneyIntelX to provide improved patient care.
  • The CANVAS study results show that risk assessment and monitoring with KidneyIntelX can help primary care physicians and our care team deliver proactive therapeutic management in early-stage diabetic kidney disease.
  • We know that by treating chronic diseases early, the benefits to the patient, health system and payers will be most significant.
  • This represents the third published, peer-reviewed clinical validation study and the first multinational study for KidneyIntelX.

Worldwide Chronic Kidney Disease Industry to 2026 - North America is Expected to Hold the Largest Market Share - ResearchAndMarkets.com

Retrieved on: 
Friday, January 7, 2022
Health, Pharmaceutical, Janssen Pharmaceuticals, Blood, National Kidney Foundation, International Society, Food, Chronic kidney disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Kidney, SGLT2, Glomerular filtration rate, Growth, Therapy, Man, Patient, ISN, Cancer, Prevalence, Death, End Stage Renal Disease Program, Kidney disease, List of international sports federations, Disease, Kidney cancer, International Society of Nephrology, CKD, Type 2 diabetes, Creatinine, FDA, Woman, Boehringer Ingelheim, Canadian International Council, Diagnosis, ESRD, Eli Lilly, Risk, Incidence, Canagliflozin, EGFR, American Cancer Society, International Journal of Nephrology and Renovascular Disease, Pharmaceutical industry, Nephrology

The glomerular filtration rate (eGFR) is calculated to evaluate u milliliters of waste the kidney is able to filter in a minute.

Key Points: 
  • The glomerular filtration rate (eGFR) is calculated to evaluate u milliliters of waste the kidney is able to filter in a minute.
  • Hence, owing to the rising prevalence of chronic kidney diseases the market is expected to witness high growth over the forecast period.
  • North America held the largest market share in previous years and is anticipated to do the same in the forecast period.
  • Thus, the presence of these market propelling factors in this region is anticipated to offer lucrative growth to the market.